Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 58

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2018

Summary

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) pipeline Target constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes.

The latest report Steroid 17 Alpha Hydroxylase17,20 Lyase - Pipeline Review, H2 2018, outlays comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Steroid 17-alpha-hydroxylase/17, 20 lyase is an enzyme belonging to hydroxylase class that is encoded by CYP17A1 gene. It helps in conversion of pregnenolone and progesterone to their 17-alpha-hydroxylated products and subsequently to dehydroepiandrosterone (DHEA) and androstenedione. It catalyzes both the 17-alpha-hydroxylation and the 17, 20-lyase reaction. It is involved in sexual development during fetal life and at puberty.

The molecules developed by companies in Pre-Registration, Phase II and Preclinical stages are 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Breast Cancer, Metastatic Breast Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Prostate Cancer, Peritoneal Cancer and Prostate Cancer.

Furthermore, this report also reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)

- The report reviews Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects

- The report assesses Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Overview
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Companies Involved in Therapeutics Development
DisperSol Technologies LLC
Johnson & Johnson
Millennium Pharmaceuticals Inc
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Drug Profiles
abiraterone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abiraterone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
abiraterone acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LAE-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orteronel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seviteronel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP17 for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CYP17 Lyase for Breast Cancer and Castration Resistant Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Dormant Products
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Discontinued Products
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Product Development Milestones
Featured News & Press Releases
Jun 06, 2018: NICE set to deny access to UK-discovered Zytiga (abiraterone acetate) with androgen deprivation therapy (ADT) for men with aggressive, early prostate cancer
May 16, 2018: Janssen to Present Data on ZYTIGA at ASCO 2018
Feb 15, 2018: Health Canada Approves New Indication for ZYTIGA (abiraterone acetate), Broadening its Use for Treatment of Newly Diagnosed Metastatic Prostate Cancer
Feb 08, 2018: ZYTIGA (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Feb 08, 2018: ZYTIGA (abiraterone acetate) Plus Prednisone Approved for Treatment of Earlier Form of Metastatic Prostate Cancer
Jan 25, 2018: Janssen to Present data on ZYTIGA at Prostate and Urothelial Cancers at ASCO GU 2018
Jan 18, 2018: Amerigen's petition leads to U.S. Zytiga patent invalidation
Jan 17, 2018: Argentum Pharmaceuticals Wins Patent Invalidation Trial against the Sole Remaining Patent Protecting Janssens ZYTIGA
Jan 17, 2018: Johnson & Johnson Issues Statement on ZYTIGA Inter Partes Reviews
Dec 05, 2017: Moffitt Cancer Center Uses Innovative Treatment Strategy to Overcome Drug Resistance
Nov 22, 2017: European Medicines Agency approves abiraterone combined with hormone therapy as first-line treatment for advanced prostate cancer
Nov 20, 2017: European Commission Extends License for Janssen's ZYTIGA Plus Prednisone / Prednisolone to Include Earlier Stage Prostate Cancer Patients
Oct 13, 2017: CHMP Issues a Positive Opinion on Janssen's ZYTIGA to Include Earlier Stage Prostate Cancer Patients
Sep 14, 2017: Janssen Submits Supplemental New Drug Application to U.S. FDA for ZYTIGA (abiraterone acetate) to Treat Men with Earlier Stages of Metastatic Prostate Cancer
Sep 08, 2017: New Data Presented at ESMO 2017 Shows That Abiraterone Acetate Plus Prednisone Provides Benefits in Patient Reported Outcomes in Both Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by DisperSol Technologies LLC, H2 2018
Pipeline by Johnson & Johnson, H2 2018
Pipeline by Millennium Pharmaceuticals Inc, H2 2018
Dormant Projects, H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
  • Global and United States Propolis Market Research by Company, Type & Application 2013-2025
    Published: 15-Jul-2018        Price: US 2000 Onwards        Pages: 152
    Summary Market Segment as follows: By Type - Supercritical Extraction CO2 (SFE) - Ethanol Extracted Propolis (EEP) - Glycol Extracted Propolis (GEP) - Others By Application - Food Industry - Cosmetic Industry - Pharmaceutical Industry - Others By Company - Apis Flora - Wax Green - Comvita - Polenectar - King's Gel - MN Propolis - Evergreen - Ponlee - ......
  • Global and United States Saffron Extract Market Research by Company, Type & Application 2013-2025
    Published: 15-Jul-2018        Price: US 2000 Onwards        Pages: 123
    Summary Market Segment as follows: By Type - Thread - Powder - Liquid By Application - Food - Medical & Pharmaceuticals - Cosmetics - Others By Company - Safrante Global Company S.L.U. - Evolva - Rowhani Saffron Co - Sara Nuts - Tarvand Saffron Co - Hijos de Eustaquio Abad & Co. S.L. - USMS Saffron Co.Inc - Royal Saffron Company - Saharkhiz International Gro......
  • Global and United States Recombinant Protein Drugs Market Research by Company, Type & Application 2013-2025
    Published: 14-Jul-2018        Price: US 2000 Onwards        Pages: 130
    Summary Market Segment as follows: By Type - Recombinant DNA - Recombinant RNA By Application - Pharmaceutical Industry - Others By Company - Novo Nordisk - Amgen - Sanofi - Eli Lilly - Merck Serono - Ortho Biotech - Roche - Kyowa Hakko Kirin - Pharmingen - Abcam - GenSci - SL PHARM - Dongbao Pharm - Ankebio - NCPC - Heng Rui......
  • Global and United States Nano Pharmaceutical Market Research by Company, Type & Application 2013-2025
    Published: 13-Jul-2018        Price: US 2000 Onwards        Pages: 131
    Summary Market Segment as follows: By Type - Natural Material Carrier - High Polymer Material Carrier By Application - Medical - Scientific Research - Others By Company - Sanofi - Merck - Pfizer - Cerulean Pharma - Selecta Biosciences - Nanobiotix - Magforce - Celgene - Celsion Corporation - Novsrtisnamiyaow - GSK - Eli Lilly - Astrazeneca......
  • Global and United States P2X Purinoceptor 3 Market Research by Company, Type & Application 2013-2025
    Published: 13-Jul-2018        Price: US 2000 Onwards        Pages: 121
    Summary Market Segment as follows: By Type - OSX-300 - ASN-009 - BLU-5937 - Others By Application - Abdominal Pain - Endometriosis - Idiopathic Pulmonary Fibrosis - Insomnia - Interstitial - Others By Company - Asana BioSciences LLC - Bayer AG - BELLUS Health Inc - Integral Molecular Inc - Merck & Co Inc - Neurim Pharmaceuticals Ltd - Pfizer Inc......
  • Global Streptokinase Market Research Report 2018
    Published: 13-Jul-2018        Price: US 2900 Onwards        Pages: 96
    This report studies the global Streptokinase market status and forecast, categorizes the global Streptokinase market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Streptokinase market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 2018-2025. The major ......
  • Investigation Report on Chinese Epoetin Alfa Market, 2018-2022
    Published: 13-Jul-2018        Price: US 2200 Onwards        Pages: 30
    Description Epoetin Alfa refers to erythropoietin (EPO). EPO in the human body is a hormone-like substance secreted by the kidneys and liver to promote erythropoiesis. The indications for EPO approved in China are renal anemia, chemotherapy-induced anemia, and perioperative erythrocyte mobilization. In Jun. 1989, FDA-approved Epoetin Alfa was launched in the U.S. in the trade name of "Epogen". It is sold in over 40 countries nowadays. The report in ......
  • Investigation Report on Chinese Pregabalin Market, 2018-2022
    Published: 13-Jul-2018        Price: US 2200 Onwards        Pages: 30
    Description Pregabalin is a new-generation drug for neuralgia treatment. In Jul. 2004, it was approved by the European Union to treat some epileptic seizures in adults. In Dec. 2004, it was approved by the U.S. Food and Drug Administration (FDA) to treat diabetic peripheral neuralgia and postherpetic neuralgia. In 2006, generalized anxiety disorder and social anxiety disorder became new indications of Pregabalin. In 2007, Pregabalin was approved by the FDA as the first drug to tre......
  • 2018-2023 Global Intravesical Bacillus Calmette Consumption Market Report
    Published: 12-Jul-2018        Price: US 4660 Onwards        Pages: 135
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Intravesical Bacillus Calmette market for 2018-2023. Intravesical Bacillus Calmette is used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs